Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma

Jason T. Romancik, MD, Pamela B. Allen, MD MSc, Edmund K. Waller, PhDMD, Zhengjia Chen, PhD, Kelly Valla, PharmD, Kaylan Dixon, BS, David J. Reagan, Amanda B. Colbert, Cecilia Rosand, PA-C, Alexandra Palmer, NP-C, Christopher Flowers, MDMS, Jonathon B. Cohen, MDMS

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-141030

Published: 2020

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, MD, Ajay K Nooka, MDMPH, Leonard Heffner, MD, Craig E. Cole, MD, J Christine Ye, MDMSc, Ravi Vij, MBBS, Craig C Hofmeister, MDMPH, John Rushton, PhD, Zhengjia Chen, PhD, Zhao Chang, PhD, Munevver Cinar, MD, Daniel Auclair, Sagar Lonial, Jonathan L. Kaufman, MD

Blood (2019) 134 (Supplement_1): 3188.

https://doi.org/10.1182/blood-2019-131223

Published: 2019

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, MD, Craig E. Cole, MD, Leonard Heffner, MD, Ajay K Nooka, MDMPH, Ravi Vij, MBBS, Nyaya Kelkar, Akshata Sridhar, Munevver Cinar, MD, Zhengjia Chen, PhD, Zhao Chang, PhD, Sagar Lonial, MD, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2018-99-119337

Published: 2018

Journal Articles

An Investigation of Potential Prognostic Factors in Late Relapse Diffuse Large B-Cell Lymphoma Patients

Wilton Edward Robinson, Jr., MPH, Yuzi Zhang, Zhengjia Chen, PhD, Oscar Calzada, BS, Michael C Churnetski, BS, Christopher Flowers, MD, Jonathon B Cohen, MDMS

Blood (2017) 130 (Supplement 1): 5220.

https://doi.org/10.1182/blood.V130.Suppl_1.5220.5220

Published: 2017

Journal Articles

Results of Interim PET/CT Imaging during Front-Line Induction in Follicular Lymphoma Do Not Predict Survival Outcomes

Max L. Goldman, BA, Chaejin Kim, PharmD, Zhengjia Chen, PhD, Oscar Calzada, BS, Michael C Churnetski, BS, Christopher Flowers, MD, Jonathon B Cohen, MDMS

Blood (2017) 130 (Supplement 1): 5156.

https://doi.org/10.1182/blood.V130.Suppl_1.5156.5156

Published: 2017

Journal Articles

High-Risk FLIPI Score at Diagnosis Is Associated with Early Relapse in the Rituximab Era for Patients with Follicular Lymphoma

Max L. Goldman, BA, Chaejin Kim, PharmD, Zhengjia Chen, PhD, Oscar Calzada, BS, Michael C Churnetski, BS, Christopher Flowers, MD, Jonathon B Cohen, MDMS

Blood (2017) 130 (Supplement 1): 5158.

https://doi.org/10.1182/blood.V130.Suppl_1.5158.5158

Published: 2017

Journal Articles

Surveillance Imaging during First-Remission in Follicular Lymphoma Does Not Impact Overall Survival

Max L. Goldman, BA, Chaejin Kim, PharmD, Zhengjia Chen, PhD, Oscar Calzada, BS, Michael C Churnetski, BS, Christopher Flowers, MD, Jonathon B Cohen, MDMS

Blood (2017) 130 (Supplement 1): 1501.

https://doi.org/10.1182/blood.V130.Suppl_1.1501.1501

Published: 2017

Journal Articles

Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies

Leon Bernal-Mizrachi, MD, Ajay K Nooka, MD MPH, Chandra Pooja, MD, Monica S Chatwal, Sungjin Kim, MS, Zhengjia Chen, PhD, Jeanne Kowalski, PhD, Jonathan L. Kaufman, MD, Sagar Lonial, MD

Blood (2014) 124 (21): 2525.

https://doi.org/10.1182/blood.V124.21.2525.2525

Published: 2014

Journal Articles

Outcomes for Myeloma in the Era of Lenalidomide Maintenance Are Not Different Among Ethnic Groups Following Autologous Transplant

Chandra Pooja, MD, Ajay K. Nooka, MD MPH, Monica S. Chatwal, MD, Sungjin Kim, MS, Zhengjia Chen, PhD, Jeanne Kowalski, PhD, Jonathan L. Kaufman, MD, Sagar Lonial, MD, Leon Bernal-Mizrachi, MD

Blood (2014) 124 (21): 3973.

https://doi.org/10.1182/blood.V124.21.3973.3973

Published: 2014

Journal Articles

Predictors Of Survival Outcomes In Phase I Relapsed Or Refractory Multiple Myeloma Patients

R. Donald Harvey, PharmD, Meagan S. Barbee, PharmD, Ajay K. Nooka, MD, MPH, Sungjin Kim, MS, Zhengjia Chen, PhD, Leonard T. Heffner, MD, Jonathan L. Kaufman, MD, Sagar Lonial, M.D.

Blood (2013) 122 (21): 1958.

https://doi.org/10.1182/blood.V122.21.1958.1958

Published: 2013

Journal Articles

Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma

Sampath Ramachandiran, PhD, Xiangxue Guo, PhD, Laurent Garderet, MD, Souhila Ikhlef, MD, Jean El-cheikh, MD, Michael R Weil, PhD, Andrew N Young, M. D., Ph.D., Mahir Bagirov, Sagar Lonial, MD, Zhengjia Chen, PhD, Jeanne Kowalsky, PhD, Yuhong Du, Ph.D, Hanna J. Khoury, MD, Susan Sunay, Jonathan L. Kaufman, MD, Lawrence H. Boise, PhD, Michael Rossi, PhD, Leon Bernal-Mizrachi, MD

Blood (2011) 118 (21): 2891.

https://doi.org/10.1182/blood.V118.21.2891.2891

Published: 2011

NARROW

Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

An Investigation of Potential Prognostic Factors in Late Relapse Diffuse Large B-Cell Lymphoma Patients

Results of Interim PET/CT Imaging during Front-Line Induction in Follicular Lymphoma Do Not Predict Survival Outcomes

High-Risk FLIPI Score at Diagnosis Is Associated with Early Relapse in the Rituximab Era for Patients with Follicular Lymphoma

Surveillance Imaging during First-Remission in Follicular Lymphoma Does Not Impact Overall Survival

Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies

Outcomes for Myeloma in the Era of Lenalidomide Maintenance Are Not Different Among Ethnic Groups Following Autologous Transplant

Predictors Of Survival Outcomes In Phase I Relapsed Or Refractory Multiple Myeloma Patients

Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only